Company intelligence / Profile preview
Nine Square Therapeutics
San Francisco, California, United Statesninesquaretx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company is developing novel Parkin activators for Parkinson's disease and has received a $4.5 million grant from The Michael J. Fox Foundation. They also have programs for ALS in preclinical stage and TRPML1 agonists for neurodegenerative diseases in discovery phase.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small moleculesChemical drugs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nine Square Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nine Square Therapeutics.